Redeye is increasingly optimistic about BI-1808. In the latest readout presented at ASH, 6 out of 13...
Systemair’s Q2 report was stronger than anticipated across the board.
* Capitalising on increased insecurity within society * Focus on core operations is starting to bear...
* CEO Oliver Lundgren highlighted Skolon surpassing 1m paying users * Skolon has now reached 50% pen...
* Maintaining long-term partnerships * Defence continues to be a fast-growing sector * Trading ~20% ...
* We hosted CEO John Vestberg at Investor Days * Strong shift towards stable recurring revenue model...
* CEO highlighted potential future M&A * Finding the balance between efficiency and individuality * ...
Fastators omsättning minskar, samtidigt som förlusten har halverats under perioden.
Last evening, Guard Therapeutics announced its evaluation of the complete results from the phase IIb...
Redeye comments on the survival readout in the phase IIb study TRIFOUR, which investigates nadunolim...
Redeye provides a comment on the webcast of 4 December, which provided more details on the negative ...
* Riding the infrastructure spending wave * Internal efficiency improvements to continue * 8-6x EBIT...
Redeye finds the subscription rate somewhat lacklustre, although since the issue was fully guarantee...
* SATCOM demand is strong * There is good, untapped potential with Ovzon-3 * The stock trades at 13x...
Redeye returns with an update on Sprint Bioscience following recent events and the Q3 report.
Incap acquires Lacon which has production sites in Germany and in Romania.
Redeye updates valuation and estimates to reflect the upcoming spin-off of Coffee Stain, which is du...
Redeye comments on the negative phase II readout and changes its base case.
Nettoomsättningen uppgick till 0,3 MSEK (0,9) och övriga rörelseintäkter till 0,8 MSEK (1,2), vilket...
* Strong potential for margin improvements * Short term priorities presented * Favourable sales mix ...
